ReviewReviews in endocrine & metabolic disorders2021
Theranostics in neuroendocrine tumors: an overview of current approaches and future challenges.
Review in Reviews in endocrine & metabolic disorders, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 49 citations in OpenAlex.
- The prognostic effect of dualBMC gastroenterology · 2026Article
- Theranostic Applications of Microrobots: Integrating Diagnostics and Precision Drug Delivery.Current drug discovery technologies · 2026Review
- Engineered GLP-1R-targeting nanoplatforms: multimodal therapeutics in human diseases.Journal of nanobiotechnology · 2025Review
- Endoscopic endonasal surgery using indocyanine green fluorescence endoscope for Cushing's disease caused by mixed intrasellar gangliocytoma and adrenocorticotropin adenoma: illustrative case.Journal of neurosurgery. Case lessons · 2025Article
- Evaluating Prognosis of Gastrointestinal Metastatic Neuroendocrine Tumors: Constructing a Novel Prognostic Nomogram Based on NETPET Score and Metabolic Parameters from PET/CT Imaging.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Carrier systems of radiopharmaceuticals and the application in cancer therapy.Cell death discovery · 2024Review
- Expression and clinical value of CXCR4 in high grade gastroenteropancreatic neuroendocrine neoplasms.Frontiers in endocrinology · 2024Article
- Improving susceptibility of neuroendocrine tumors to radionuclide therapies: personalized approaches towards complementary treatments.Theranostics · 2024Review
- Scandium Radioisotopes-Toward New Targets and Imaging Modalities.Molecules (Basel, Switzerland) · 2023Review
- Preoperative detection of functional somatostatin receptors in a patient with an insulinoma.Clinical case reports · 2023Article
- Advances in the Treatment of Gastroenteropancreatic Neuroendocrine Carcinomas: Are we Moving Forward?Endocrine reviews · 2023Review
- Theranostic in GLP-1R molecular imaging: challenges and emerging opportunities.Frontiers in molecular biosciences · 2023Review
- Epigenetic regulation of SSTFrontiers in endocrinology · 2023Article
- Metastatic medullary thyroid carcinoma: a new way forward.Endocrine-related cancer · 2022Review
- New Directions in Imaging Neuroendocrine Neoplasms.Current oncology reports · 2021Review
- First-in-Humans Study of the SSTR AntagonistJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021Article
- Distinctive detection of insulinoma using [Scientific reports · 2021Article
- Theranostic Advances in Breast Cancer in Nuclear Medicine.International journal of molecular sciences · 2021Review
- Comparison of 68Ga-DOTANOC and 18F-FDG PET-CT Scans in the Evaluation of Primary Tumors and Lymph Node Metastasis in Patients With Rectal Neuroendocrine Tumors.Frontiers in endocrinology · 2021Article
- Somatostatin receptors in normal and acromegalic somatotroph cells: the U-turn of the clinician to immunohistochemistry report - a review.Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologieReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 3 countries.
Funding
Abstract
Neuroendocrine neoplasms (NENs) comprise a heterogeneous group of tumors, mainly localized in the gastrointestinal system. What characterizes NENs is the expression of hormone receptors on the tumor cell surface, making them accessible for diagnostic and therapeutic approaches (theranostics) using radiolabelled peptides. Somatostatin receptors subtype-two (SST2) play an important role in NENs since they are overexpressed and homogeneously distributed at the surface of the majority of NENs. Accordingly, targeting SST2 for diagnostic and therapeutic purposes has been established. Current research aims at upregulating its expression by epigenetic treatment or improving its targeting via use of alternative radioligands. In addition, recent data suggest a future role of SST antagonists as a diagnostic tool and a potential therapeutic option. Another promising target is the glucagon-like peptide-1 (GLP-1) receptor. Targeting GLP-1R using exendin-4 (GLP-1 analogue) has a high sensitivity for the localization of the often SST2-negative sporadic insulinomas and insulinomas in the context of multiple endocrine neoplasia type-1. Further options for patients with insufficient expression of SST2 involve metaiodobenzylguanidine (MIBG) and the molecular target C-X-C motif chemokine receptor-4 (CXCR4), which have been evaluated for potential theranostic approach in symptomatic NENs or dedifferentiated tumors. Recently, new targets such as the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the fibroblast activation protein (FAP) have been identified in NENs. Finally, minigastrin - a ligand targeting the cholecystokinin-2 (CCK2) receptors in medullary thyroid carcinoma and foregut neuroendocrine tumors - may improve future management of these diseases with currently limited therapeutic options. This review summarises the current approaches and future challenges of diagnostic and therapeutic evaluations in neuroendocrine neoplasms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.